BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
According to recent guidelines, long-term anticoagulation is recommended for patients with
atrial fibrillation (AF) and a risk profile with CHA2DS2-VASc score of 1 or more. Vitamin K
antagonists(VAK) and novel oral anticoagulants such as rivaroxaban are current treatment
options for AF patients with additional risk factors for stroke. Currently there are only
limited information to what extend AF patients prefer one or the other treatment option based
on patient relevant characteristics of novel oral anticoagulants vs. VKAs. It is also unknown
which of the characteristics influences patient preference most and how this relates to a
neutral comparator. Furthermore, an additional unknown factor is also how patient evaluate
their current treatment and if this leads to differences among treatment with VKAs and
rivaroxaban.